Last updated: 3 August 2023 at 8:27pm EST

Bio Venture Partners Fund I... Net Worth




The estimated Net Worth of Bio Venture Partners Fund I... is at least $8.19 Million dollars as of 1 August 2023. Bio I owns over 833,333 units of Inozyme Pharma stock worth over $8,188,771 and over the last 6 years Bio sold INZY stock worth over $0.

Bio I INZY stock SEC Form 4 insiders trading

Bio has made over 4 trades of the Inozyme Pharma stock since 2018, according to the Form 4 filled with the SEC. Most recently Bio bought 833,333 units of INZY stock worth $3,999,998 on 1 August 2023.

The largest trade Bio's ever made was buying 1,070,000 units of Inozyme Pharma stock on 19 April 2022 worth over $3,948,300. On average, Bio trades about 607,139 units every 442 days since 2018. As of 1 August 2023 Bio still owns at least 1,571,741 units of Inozyme Pharma stock.

You can see the complete history of Bio I stock trades at the bottom of the page.



What's Bio I's mailing address?

Bio's mailing address filed with the SEC is 1700 Owens St, San Francisco, CA 94158, USA.

Insiders trading at Inozyme Pharma

Over the last 4 years, insiders at Inozyme Pharma have traded over $0 worth of Inozyme Pharma stock and bought 11,149,230 units worth $104,131,475 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Inozyme Pharma executives and independent directors trade stock every 46 days with the average trade being worth of $2,019,505. The most recent stock trade was executed by Douglas A Treco on 1 April 2024, trading 25,000 units of INZY stock currently worth $130,250.



What does Inozyme Pharma do?

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.



Complete history of Bio I stock trades at Entasis Therapeutics Inc and Inozyme Pharma

Insider
Trans.
Transaction
Total value
Bio Venture Partners Fund I...
Buy $3,999,998
1 Aug 2023
Bio Venture Partners Fund I...
Buy $3,948,300
19 Apr 2022
Bio Venture Partners Fund I...
Buy $3,000,000
28 Jul 2020
Bio Venture Partners Fund I...
Buy $5,065,860
28 Sep 2018


Inozyme Pharma executives and stock owners

Inozyme Pharma executives and other stock owners filed with the SEC include: